Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: Nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Kuo, Shu Chen ^a,b,c   Chang, Shan Chwen ^d,e   Wang, Hui Ying ^a   Lai, Jui Fen ^a   Chen, Pei Chen ^a   Shiau, Yih Ru ^a   Huang, I Wen ^a   Lauderdale, Tsai Ling Y ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Acinetobacter baumannii complex; Antimicrobial resistance; Extensively drug resistant

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN;

ACINETOBACTER BAUMANNII; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BLOOD; BROTH DILUTION; EXTENSIVELY DRUG RESISTANT ACINETOBACTER BAUMANNI COMPLEX; GEOGRAPHIC DISTRIBUTION; GERIATRIC PATIENT; HUMAN; IMIPENEM RESISTANT ACINETOBACTER BAUMANNI COMPLEX; INTENSIVE CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TAIWAN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HOSPITALS; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TAIWAN;

EID: 84865319030     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-200     Document Type: Article

References (32)

1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008, 21:538-582. 10.1128/CMR.00058-07, 2493088, 18625687.
2. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007, 5:939-951. 10.1038/nrmicro1789, 18007677.
3. Neonakis IK, Spandidos DA, Petinaki E. Confronting multidrug-resistant Acinetobacter baumannii: a review. Int J Antimicrob Agents 2011, 37:102-109. 10.1016/j.ijantimicag.2010.10.014, 21130607.
4. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007, 51:3471-3484. 10.1128/AAC.01464-06, 2043292, 17646423.
5. Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, Ryu SY, Heo ST, Jung DS, Rhee JY, et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007, 59:525-530. 10.1093/jac/dkl499, 17213265.
6. Sunenshine RH, Wright M-O, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE, Anderson A, Carnell J, Jernigan DB, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007, 13:97-103. 10.3201/eid1301.060716, 2725827, 17370521.
7. Peleg AY, Paterson DL. Multidrug-resistant Acinetobacter: a threat to the antibiotic era. Intern Med J 2006, 36:479-482. 10.1111/j.1445-5994.2006.01130.x, 16866649.
8. Turner PJ. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis 2008, 60:185-192. 10.1016/j.diagmicrobio.2007.09.006, 17945455.
9. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011, 66:2070-2074. 10.1093/jac/dkr239, 21715434.
10. Jean S-S, Hsueh P-R. High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents 2011, 37:291-295. 10.1016/j.ijantimicag.2011.01.009, 21382699.
11. Lauderdale TL, Clifford McDonald L, Shiau YR, Chen PC, Wang HY, Lai JF, Ho M. The status of antimicrobial resistance in Taiwan among gram-negative pathogens: the Taiwan surveillance of antimicrobial resistance (TSAR) program, 2000. Diagn Microbiol Infect Dis 2004, 48:211-219. 10.1016/j.diagmicrobio.2003.10.005, 15023432.
12. White AR, . Surveillance BWPoR The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: a successful collaborative model. J Antimicrob Chemother 2008, 62(2):ii3-ii14. 10.1093/jac/dkn348, 18819978, Surveillance BWPoR.
13. Tseng SH, Lee CM, Lin TY, Chang SC, Chang FY. Emergence and spread of multi-drug resistant organisms: think globally and act locally. J Microbiol Immunol Infect 2011, 44:157-165. 10.1016/j.jmii.2011.03.001, 21524608.
14. Jean S-S, Hsueh P-R, Lee W-S, Chang H-T, Chou M-Y, Chen I-S, Wang J-H, Lin C-F, Shyr J-M, Ko W-C, et al. Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in Intensive Care Units in Taiwan: SMART programme data 2005. Int J Antimicrob Agents 2009, 33:266-271. 10.1016/j.ijantimicag.2008.08.026, 19091522.
15. Ho M, McDonald LC, Lauderdale TL, Yeh LL, Chen PC, Shiau YR. Surveillance of antibiotic resistance in Taiwan, 1998. J Microbiol Immunol Infect 1999, 32:239-249.
16. Chen FJ, Huang IW, Wang CH, Chen PC, Wang HY, Lai JF, Shiau YR, Lauderdale TL. mecA-positive Staphylococcus aureus with low-level oxacillin MIC in Taiwan. J Clin Microbiol 2012, 50:1679-1683. 10.1128/JCM.06711-11, 22378906.
17. Wu H, Wang JT, Shiau YR, Wang HY, Lauderdale TL, Chang SC. A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. J Microbiol Immunol Infect 2012, 45:120-126. 10.1016/j.jmii.2011.09.028, 22154599.
18. Schreckenberger PC, von Graevenitz A. Acinetobacter, Achromobacter, Alcaligenes, Moraxella, and other nonfermentative Gram-negative rods. p. 539-560. Manual of Clinical Microbiology 1999, American Society for Microbiology, Washington, D.C., Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, 7.
19. Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility testing; Twenty-First Information Supplement 2011, CLSI document M100-S21, CLSI, Wayne, PA, Clinical and Laboratory Standards Institute (CLSI).
20. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18:268-281. 10.1111/j.1469-0691.2011.03570.x, 21793988.
21. Tan TY, Lim TP, Lee WH, Sasikala S, Hsu LY, Kwa AL. In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and Etest methods. Antimicrob Agents Chemother 2011, 55:436-438. 10.1128/AAC.00850-10, 3019682, 20956606.
22. Stelling JM, O'Brien TF. Surveillance of antimicrobial resistance: the WHONET program. Clin Infect Dis 1997, 24(Suppl 1):S157-168.
23. Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX, Stern Y. Physical activity, diet, and risk of Alzheimer disease. JAMA 2009, 302:627-637. 10.1001/jama.2009.1144, 2765045, 19671904.
24. Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007, 60:1018-1029. 10.1093/jac/dkm310, 17855724.
25. Falagas ME, Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006, 64:7-15. 10.1016/j.jhin.2006.04.015, 16822583.
26. Lin MF, Kuo HY, Yeh HW, Yang CM, Sung CH, Tu CC, Huang ML, Liou ML. Emergence and dissemination of bla(OXA-23)-carrying imipenem-resistant Acinetobacter sp. in a regional hospital in Taiwan. J Microbiol Immunol Infect 2011, 44:39-44. 10.1016/j.jmii.2011.01.008, 21531351.
27. Lu PL, Doumith M, Livermore DM, Chen TP, Woodford N. Diversity of carbapenem resistance mechanisms in Acinetobacter baumannii from a Taiwan hospital: spread of plasmid-borne OXA-72 carbapenemase. J Antimicrob Chemother 2009, 63:641-647. 10.1093/jac/dkn553, 19182237.
28. Su CH, Wang JT, Hsiung CA, Chien LJ, Chi CL, Yu HT, Chang FY, Chang SC. Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: association with hospital antimicrobial usage. PLoS One 2012, 7:e37788. 10.1371/journal.pone.0037788, 3357347, 22629456.
29. Smani Y, Lopez-Rojas R, Dominguez-Herrera J, Docobo-Perez F, Marti S, Vila J, Pachon J. In vitro and in vivo reduced fitness and virulence in ciprofloxacin-resistant Acinetobacter baumannii. Clin Microbiol Infect 2012, 18:E1-E4. 10.1111/j.1469-0691.2011.03695.x, 22084991.
30. Cao J, Song W, Gu B, Mei YN, Tang JP, Meng L, Yang CQ, Wang H, Zhou H. Correlation between carbapenem consumption and antimicrobial resistance rates of Acinetobacter baumannii in a university-affiliated hospital in China. J Clin Pharmacol 2012, Feb 02 [Epub ahead of print].
31. Ko KS, Suh JY, Kwon KT, Jung S-I, Park K-H, Kang CI, Chung DR, Peck KR, Song J-H. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 2007, 60:1163-1167. 10.1093/jac/dkm305, 17761499.
32. Farrell DJ, Turnidge JD, Bell J, Sader HS, Jones RN. The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). J Infect 2010, 60:440-451. 10.1016/j.jinf.2010.03.024, 20361999.